Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Perspectives on the Migraine Pipeline

Posted by Matt Breese on Jan 16, 2018

Approximately 39 million Americans are affected by migraines, according to the Modern Medicine Network.
 
Several drug developers are working to expand treatment options for migraines.  In 2018, we'll see more activity in the specialty migraine pipeline. 
 
Read More

Topics: Specialty

MMIT Reality Check on Diabetes (Dec 2017)

Posted by Matt Breese on Dec 31, 2017

According to our recent payer coverage analysis for type 2 diabetes treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Which Disease Areas Are On Your Mind Going Into 2018?

Posted by Matt Breese on Dec 31, 2017

We reviewed activity across major disease areas featured in 2017 MMIT Reality Checks and gathered poll data from pharma brand teams to understand where the biggest buzz is within market access. The following disease areas (in order) is where we received the most interest - some of these surprised us...

Read More

Topics: Specialty, Industry Trends, Market Access, Branding & Marketing

MMIT Reality Check on Hemophilia (Dec 2017)

Posted by Matt Breese on Dec 20, 2017

According to our recent payer coverage analysis for hemophilia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Perspectives on Kidney Cancer

Posted by Matt Breese on Dec 19, 2017

There has been an increasing prevalence of kidney cancer during the past decade. Several pharma manufacturers are stepping up to the plate with promising treatment options. Through 2024, the global market for kidney cancer drugs is expected to continue to grow. 
 
According to an analysis conducted by Grand View Research"The Asia-Pacific market is estimated to witness the fastest growth rate for the kidney cancer drugs market."
 
Read More

Topics: Specialty, Market Access

Trends That Matter for Viscosupplements

Posted by Matt Breese on Dec 14, 2017

In our weekly Trends that Matter series, we provide infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is viscosupplements,. 

According to our recent payer coverage analysis for viscosupplements, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

Read More

Topics: Specialty, Industry Trends

Trends That Matter for Multiple Sclerosis

Posted by Matt Breese on Dec 7, 2017

In our weekly Trends that Matter series, we provide infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is multiple sclerosis treatments. 

According to our recent payer coverage analysis for multiple sclerosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

Read More

Topics: Specialty, Industry Trends

Perspectives on the Anti-Epilepsy Pipeline

Posted by Matt Breese on Dec 5, 2017

As 2018 approaches, the anti-epilepsy market is getting more attention in the pharma scene. The significant drivers of growth in this area are the development of third generation drugs, increased screening of patients, and improved access to anti-epilepsy treatments. 
 
Significant market constraints include the high cost of clinical trials and the need for high-level post market surveillance.
 
Read More

Topics: Specialty, Market Access

MMIT Reality Check on Multiple Sclerosis (Nov 2017)

Posted by Matt Breese on Nov 30, 2017

According to our recent payer coverage analysis for multiple sclerosis treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on G-CSF (Nov 2017)

Posted by Matt Breese on Nov 19, 2017

According to our recent payer coverage analysis for G-CSF treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing